Synairgen surges on FDA fast track status for Covid-19
Shares in respiratory and drug discovery company Synairgen (SNG:AIM) surged 36% to 148.3p on Friday after it received fast track status from the US FDA (Food and Drug Administration).This means shorter review timelines from the FDA...
18 December 2020